Krensavage Asset Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 18, 2025), Krensavage Asset Management, LLC reported 12 stock positions worth $169.0 million. Its top holding was United Therapeutics (UTHR) at 19.2% of the portfolio, followed by Exelixis (EXEL, 19.0%) and Cardinal Health (CAH, 14.6%). Compared with Q3 2024, it sold out of 1, added to 2 and reduced 10. The biggest buy was Indivior (INDV, shares +33%) and the biggest sale Biogen (BIIB, shares −4%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001609251
- Portfolio Value
- $169.0M (Q4 2024)
- SEC Filing
- 0001609251-25-000002 ↗ filed Feb 18, 2025
Holdings Value
Holdings 12 stocks · $169.0M
| UTHR United Therapeutics Corp. | 19.22% | 92,057 | $32.5M | Reduce -8.3% |
| EXEL Exelixis Inc. | 19.03% | 965,866 | $32.2M | Reduce -24.6% |
| CAH Cardinal Health Inc. | 14.61% | 208,845 | $24.7M | Reduce -0.7% |
| BIIB Biogen Inc. | 9.85% | 108,923 | $16.7M | Reduce -4.0% |
| JAZZ Jazz Pharmaceuticals PLC | 7.71% | 105,803 | $13.0M | Reduce -4.0% |
| ENTA Enanta Pharmaceuticals Inc. | 7.20% | 2,117,390 | $12.2M | Add +41.3% |
| INDV Indivior Ltd. | 6.88% | 935,680 | $11.6M | Add +33.3% |
| BNTX Biontech SE-ADR | 5.98% | 88,663 | $10.1M | Reduce -5.3% |
| SNY Sanofi-ADR | 4.26% | 149,196 | $7.2M | Reduce -0.7% |
| ALKS Alkermes PLC | 4.05% | 238,136 | $6.8M | Reduce -5.3% |
| VNDA Vanda Pharmaceuticals Inc. | 1.07% | 378,762 | $1.8M | Reduce -8.7% |
| MURA Mural Oncology PLC | 0.13% | 70,163 | $226K | Reduce -7.5% |
Portfolio Sells Q3 2024 → Q4 2024
| BIIB Biogen Inc. | Reduce -4.0% | 9.85% | −2.47 |
| UTHR United Therapeutics Corp. | Reduce -8.3% | 19.22% | −0.93 |
| SNY Sanofi-ADR | Reduce -0.7% | 4.26% | −0.59 |
| BNTX Biontech SE-ADR | Reduce -5.3% | 5.98% | −0.25 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −0.21 |
| VNDA Vanda Pharmaceuticals Inc. | Reduce -8.7% | 1.07% | −0.02 |
| MURA Mural Oncology PLC | Reduce -7.5% | 0.13% | +0.00 |
| ALKS Alkermes PLC | Reduce -5.3% | 4.05% | +0.11 |
| EXEL Exelixis Inc. | Reduce -24.6% | 19.03% | +0.39 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -4.0% | 7.71% | +0.83 |
| CAH Cardinal Health Inc. | Reduce -0.7% | 14.61% | +1.59 |
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 18 | $263.2M | ENTA, JAZZ, UTHR, BMRN, EXEL |
| Q1 2026 | 20 | $255.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q4 2025 | 18 | $283.1M | UTHR, ENTA, BMRN, JAZZ, EXEL |
| Q3 2025 | 17 | $234.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q2 2025 | 15 | $188.9M | UTHR, CAH, EXEL, JAZZ, ENTA |
| Q1 2025 | 14 | $180.9M | EXEL, UTHR, CAH, SUPN, JAZZ |
| Q4 2024Amended | 12 | $169.0M | UTHR, EXEL, CAH, BIIB, JAZZ |
| Q3 2024 | 13 | $178.5M | UTHR, EXEL, CAH, BIIB, ENTA |
| Q2 2024 | 13 | $217.8M | EXEL, UTHR, BIIB, TARO, CAH |
| Q1 2024 | 12 | $225.5M | EXEL, UTHR, BIIB, TARO, CAH |